熱門詞： 進(jìn)口電動溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進(jìn)口電動溫度調(diào)節(jié)閥數(shù)據(jù)表進(jìn)口電動高溫調(diào)節(jié)閥-德國進(jìn)口電動高溫法蘭調(diào)節(jié)閥進(jìn)口電動蒸汽調(diào)節(jié)閥-德國進(jìn)口電動蒸汽調(diào)節(jié)閥
熱門詞： 進(jìn)口電動溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進(jìn)口電動溫度調(diào)節(jié)閥數(shù)據(jù)表進(jìn)口電動高溫調(diào)節(jié)閥-德國進(jìn)口電動高溫法蘭調(diào)節(jié)閥進(jìn)口電動蒸汽調(diào)節(jié)閥-德國進(jìn)口電動蒸汽調(diào)節(jié)閥
Symphogen 丹麥Symphogen
Symphogen是一家私營生物制藥公司， 70多個(gè)雇員，總部設(shè)在丹麥?zhǔn)锥几绫竟?br/>
Symphogen is the leader in developing recombinant polyclonal antibodies (rpAb), a new class of biopharmaceuticals for the treatment or prophylaxis of serious human diseases.
Vision
Symphogen’s vision is to create superior antibody therapeutics by decoding the wisdom of nature.
Mission
With its pioneering antibody discovery and manufacturing technologies, Symphogen aims to create, develop, manufacture and commercialize target-specific recombinant antibodies that mirror the natural diversity and specificity of the human immune response. Symphogen is building a proprietary product pipeline within several core areas, including the replacement of plasma-derived immunoglobulins, infectious diseases, and cancer.
Symphogen's lead candidate, Sym001 (anti-RhD) for the treatment of Idiopathic Thrombocytopenic Purpura (ITP) and the prevention of Hemolytic Disease in Newborns (HDN), became the first recombinant polyclonal antibody composition to enter clinical evaluation when Phase 1 trials were initiated in March of 2007.
Symphogen was founded in 2000 and is backed by a leading international venture capital investor syndicate.
Symphogen’s headquarters are located in Copenhagen, Denmark.
知識產(chǎn)權(quán)侵權(quán)投訴：不生產(chǎn)任何產(chǎn)品所有產(chǎn)品均來自產(chǎn)品的生產(chǎn)廠商、代理商、經(jīng)銷商，如有侵權(quán)請聯(lián)系：400-006-7520 ，我們會在第一時(shí)間處理
本網(wǎng)站所有產(chǎn)品與藥品無關(guān)
滬公網(wǎng)安備31011502016460號
